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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel foods and
Food Allergens (NDA) was asked to deliver an opinion on overall safety assessment for chia seeds
(Salvia hispanica L.) as a novel food (NF) pursuant to Regulation (EU) 2015/2283 in the light of the
increasing dietary intake from the growing number of authorised uses in recent years. The safety
assessment of this NF is based on data supplied in seven applications, previous safety assessments of
chia seeds and information retrieved from an extensive literature search done by EFSA. Since none of
the applications addressed the possible formation of process contaminants, the present assessment is
limited to those proposed extended uses which do not raise safety concerns regarding the formation of
such contaminants. These include the use of whole and ground chia seeds added to chocolate, fruit
spreads, fruit desserts, mixed fruit with coconut milk in twin pot, fruit-preparations to underlay a dairy
product, fruit-preparations to be mixed with dairy products, confectionary (excluding chewing gums),
dairy products and analogues, edible ices, fruit and vegetables products, non-alcoholic beverages and
compotes from fruit and/or vegetables and/or with cereals. In addition, this assessment also concerns
uses of chia seeds without speciﬁc restrictions and precautions regarding their use levels in other foods
which usually do not include heat treatment during processing and cooking. Apart from allergenicity,
the Panel did not identify any hazard which causes safety concerns. Lacking the basis and need to
establish safe maximum intake levels for chia seeds, no exposure assessment was conducted. The
Panel concludes that chia seeds are safe under the assessed conditions of use.
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Summary
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel foods and
Food Allergens (NDA) was asked to deliver an opinion on overall dietary exposure and safety assessment
for chia seeds (Salvia hispanica L.) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The
assessment of the safety of this NF, which follows the methodology set out in the EFSA Guidance on the
preparation and presentation of an application for authorisation of a NF and in the Commission
Implementing Regulation (EU) 2017/2469, is based on the data supplied in seven applications: EFSA-Q-
2018-00224 (NF2018/0214), EFSA-Q-2018-00344 (NF2018/0183), EFSA-Q-2018-00681 (NF2018/0283),
EFSA-Q-2018-00682 (NF2018/0424), EFSA-Q-2018-00683 (NF2018/0469), EFSA-Q-2018-00684
(NF2018/0519) and EFSA-Q-2018-00686 (NF2018/05452), previous safety assessments of chia seeds
(EFSA NDA Panel, 2005, 2009), information provided by the EFSA Working Group on Compendium of
Botanicals, which are based on extensive literature search and ad hoc search performed by the European
Food Safety Authority (EFSA) for scientiﬁc literature related to chia seeds and process contaminants.
The NF is chia seeds (S. hispanica L.) and is currently authorised in the European Union (EU) in
accordance with Regulation (EC) No 258/97, as a NF for a number of uses as listed in Commission
Implementing Regulation (EU) 2017/2470 and in accordance with Regulation (EU) 2015/2283 in the
following food categories: bread products; baked products; breakfast cereals; fruit, nut and seed
mixes; fruit juice and fruit/vegetable blend beverages; pre-packaged chia seed as such; fruit spreads;
yoghurt; sterilised ready to eat meals based on cereal grains, pseudocereals and/or pulses.
During the safety assessment of the new uses proposed in these seven applications, the
Panel retrieved one study which investigated process contaminants in biscuits for which chia ﬂour was
partially substituting wheat ﬂour in the dough, baked at 190°C. The results indicated that different
formulations of biscuits containing chia seeds may lead to substantial increase in acrylamide. None of
the applications addressed and considered the formation of process contaminants in foods with added
chia seeds when such foods undergo thermal processing and/or cooking procedures. In the absence of
information that addresses such possible formation of a process contaminant, the safety of those
proposed uses is not assessed in this opinion and will be subject of a separate assessment.
The present assessment is therefore focused on proposed extended uses that do not raise safety
concerns regarding the formation of acrylamide (because such foods are usually not subject to thermal
processing or cooking procedures and/or are considered not to be among the relevant contributors of
this process contaminant to the overall human exposure). Thus, this assessment concerns the safety
of whole and ground chia seeds without speciﬁed maximum use levels when added to chocolate, fruit
spreads, fruit desserts, mixed fruit with coconut milk in twin pot, fruit-preparations to underlay a dairy
product, fruit-preparations to be mixed with dairy products, confectionary (excluding chewing gums),
dairy products and analogues, edible ices, fruit and vegetables products, non-alcoholic beverages and
compotes from fruit and/or vegetables and/or with cereals. In addition, this assessment also concerns
uses of chia seeds without speciﬁc restrictions and precautions regarding their use levels in other foods
which usually do not include heat treatment during processing and cooking.
In 2009, the Panel expressed the uncertainty related to the potential allergenicity of chia seeds and
noted the cross-reactivity of sera from patients known to be allergic to peanuts and sesame. Since
then, the available information from two case studies (Garcıa Jimenez et al., 2015; and Tomas-Perez
et al., 2018) indicates that allergic reactions upon consumption of chia seeds may occur.
In addition to previous safety assessments of chia seeds (EFSA NDA Panel, 2005, 2009) and based
on the information provided in the applications that are subject of the present assessment, as well as
the ones retrieved from the extensive literature search regarding composition, stability, history of
consumption, toxicological and human data regarding whole and ground chia seeds, the Panel did not
identify any other hazard which causes safety concerns.
In the absence of such hazard and thus, lacking the basis and need to establish safe maximum
intake levels for chia seeds, no exposure assessment was conducted.
The Panel concludes that chia seeds are safe under the assessed conditions of use.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
Chia seeds (Salvia hispanica L.) are authorised, in accordance with Regulation (EC) No 258/971, as
a novel food for a number of uses as listed in Commission Implementing Regulation (EU) 2017/24702
establishing the Union list of novel foods in accordance with Regulation (EU) 2015/22833. The
authorised uses of chia seeds include the following food categories: bread products, baked products,
breakfast cereals, fruit, nut and seed mixes, fruit juice and fruit/vegetable blend beverages, pre-
packaged chia seed as such, fruit spreads, yoghurt, sterilised ready to eat meals based on cereal
grains, pseudocereals and/or pulses.
The ﬁrst authorisation for placing on the Union market of chia seeds as a novel food to be used in
bread products was given by Commission Decision 2009/827/EC4 following the European Food Safety
Authority’s Opinion (EFSA NDA Panel, 2009) on safety of chia seeds (Salvia hispanica L.) as a novel
food. Subsequent authorisations of extension of use of chia seeds received under Article 4 of
Regulation (EC) No 258/97 were based on risk assessments carried out by the Member States national
authorities with no objections having been raised by the other Member States.
On 12 September 2017, the company Sanchis Mira S.A. submitted a request to the competent
authority of Spain in accordance with Article 4 of Regulation (EC) No 258/97 for an extension of use of
chia seeds in additional food category, namely, chocolate with a maximum content of 3% chia seeds.
On 25 September 2017, the competent authority of Spain forwarded to the Commission its initial
assessment report, in which it has been concluded that the extension of use and proposed maximum use
level of chia seeds met the criteria for novel food set out in Article (3) of Regulation (EC) No 258/97.
On 17 October 2017, the Commission forwarded the initial assessment report to the other Member
States. One Member State raised objections, questioning the overall safety of the novel food in light of
the 2009 EFSA NDA Panel assessment as a result of the increasing dietary intake of chia seeds from
the growing number of authorised uses. The objecting MS underlined that while individual uses,
including the proposed use in chocolate at 3%, may be safe, there is a need to assess the overall
dietary intake from all authorised uses since 2009 including the current request for the extension of
use and if necessary, revise the 2009 EFSA NDA Panel safety assessment.
Pursuant to Article 35(1) of Regulation (EU) 2015/2283, any request for placing a novel food on the
market within the Union submitted to a Member State in accordance with Article 4 of Regulation (EC)
No 258/97 and for which the ﬁnal decision has not been taken before 1 January 2018 shall be treated
as an application submitted under Regulation (EU) 2015/2283. The application also meets the
requirements laid down in Regulation (EU) 2015/2283.
In addition to the above request (NF 2018/0183), the Commission has received through its novel
food e-submission portal the following requests for the authorisation of the extension of use of chia
seeds within the meaning of Article 10 of Regulation (EU) 2015/2283:
• Extension of use in chocolate to a maximum of 10% (NF 2018/0183 and NF 2018/0469);
• Increasing the maximum levels in fruit spreads, from the currently authorised level of 1.0% to
a maximum of 10% (NF 2018/0283 and NF 2018/0214);
• Extension of use in fruit desserts at maximum level of 2.5% (NF 2018/0283);
• Extension of use in mixed fruit with coconut milk for a twin pot at maximum level of 6% (NF
2018/0283);
• Extension of use in fruit-preparations to underlay a dairy product at maximum level of 6% (NF
2018/0283);
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel foods ingredients (OJ L, 43, 14.2.1997, p. 1).
2 Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in
accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods (OJ L 351,
30.12.2017, p. 72).
3 Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001 (OJ L 327, 11.12.2015, p. 1).
4 Commission Decision 2009/827/EC of 13 October 2009 authorising the placing on the market of Chia seed (Salvia hispanica) as
novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (OJ L 294, 11.11.2009,
p. 14).
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• Extension of use in fruit-preparations to be mixed with dairy products at maximum level of 6%
(NF 2018/0283);
• Extension of use in confectionary, excluding chewing gums, at a maximum level of 10% (NF 2018/
0424 and NF 2018/0519);
• Extension of use in dairy products and analogues at a maximum level of 10% (NF 2018/0519);
• Extension of use in edible ices at a maximum level of 10% (NF 2018/0519);
• Extension of use in fruit and vegetables products at a maximum level of 10% (NF 2018/0519);
• Extension of use in cereal and cereal products at a maximum level of 10% (NF 2018/0519);
• Extension of use in bakery wares at a maximum level of 10% (NF 2018/0519);
• Extension of use in herbs, spices, seasonings, soups and broths, sauces, salads and savoury
based sandwich spreads and protein products at a maximum level of 10% (NF 2018/0519);
• Extension of use in total diet replacement foods for weight control as deﬁned by Regulation
(EU) No 609/20135, foods bearing statements on the absence or reduced presence of gluten in
accordance with the requirements of Commission Implementing Regulation (EU) No 828/20146
at a maximum level of 10% (NF 2018/0519);
• Extension of use in non-alcoholic beverages at a maximum level of 10% (NF 2018/0519);
• Extension of use in ready-to-eat savouries and snacks at a maximum level of 10% (NF 2018/
0519);
• Extension of use in desserts at a maximum level of 10% (NF 2018/0519);
• Extension of use in compotes from fruit and/or vegetables and/or with cereals at maximum
level of 2% (NF 2018/0542).
In light of the above, an overall dietary exposure and safety assessment of chia seeds is necessary
to update the 2009 EFSA NDA Panel opinion so as to ensure that the currently authorised uses
together with the prospective extensions of use mentioned above comply with the requirements of
Article 7 of Regulation (EU) 2015/2283 and to underpin the above extension of uses in line with the
requirements of Article 10 of the same Regulation.
On 16 July 2018 and in accordance with Article 10(3) of Regulation (EU) 2015/2283, the
Commission asked EFSA to provide a scientiﬁc opinion on the above listed extensions of use of chia
seeds (Salvia hispanica L.) as a novel food.
In addition, in accordance with Article 29(1) of Regulation (EC) No 178/20027, the Commission
asked EFSA to evaluate whether the safety of chia seeds as a novel food is still in accordance with the
requirements of Article 7 of Regulation (EU) 2015/2283, taking into account the overall, cumulative
intakes of chia seeds from all authorised uses and including the above extension of use.
In its opinion, EFSA should, if possible, pronounce as to whether the overall exposure, safety, and
history of consumption of chia as a novel food in Europe and as a traditional food in third countries
would support its indiscriminate uses in foods much in a similar manner that other European staple
foods are used.
2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the applications (EFSA-
Q-2018-00224, EFSA-Q-2018-00344, EFSA-Q-2018-00681, EFSA-Q-2018-00682, EFSA-Q-2018-00683,
EFSA-Q-2018-00684 and EFSA-Q-2018-00686), previous safety assessments of chia seeds (EFSA NDA
Panel, 2005, 2009), information provided by the EFSA Working Group on Compendium of Botanicals
and an ad hoc literature search performed by EFSA.
5 Regulation (EC) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009.
6 Commission Implementing Regulation (EC) No 828/2014 of 30 July 2014 on the requirements for the provision of information
to consumers on the absence or reduced presence of gluten in food.
7 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety (OJ L 31, 1.2.2002, p. I).
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Administrative and scientiﬁc requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in Commission Implementing Regulation (EU) 2017/24698.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application9. As indicated in this guidance, it is
the duty of the applicant to provide all available (proprietary, conﬁdential and published) scientiﬁc
data, including both data in favour and not in favour to support the safety of the proposed NF.
None of the NF applications under this mandate included a request for protection of proprietary
data in accordance with Article 26 of Regulation (EU) 2015/2283.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications and the
principles described in the relevant existing guidance documents from the EFSA Scientiﬁc Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of Commission Implementing Regulation (EU) 2017/2469.
The information provided by the EFSA Working Group on Compendium of Botanicals is based on an
extensive literature search on chia seeds (S. hispanica L.) using the following scientiﬁc databases:
‘Scopus’, ‘Pubmed’, ‘Sciﬁnder’ and ‘Web of Science’. This provided the basis for identifying scientiﬁc
evidence available in peer-reviewed scientiﬁc papers in relation to substances contained in chia seeds
of potential concerns, toxicological data and studies reporting adverse health outcomes in humans.
In addition, EFSA searched ad hoc for scientiﬁc literature related to chia seeds and process
contaminants.
This assessment concerns only the risk that might be associated with the consumption of the NF
under the proposed conditions of use and is not an assessment of the efﬁcacy of chia seeds with
regard to any claimed beneﬁt.
3. Assessment
3.1. Introduction
This mandate refers to the safety of the NF chia seeds (S. hispanica L.), which has been already
assessed by EFSA NDA Panel (2009) and authorised in the EU under the conditions of use as speciﬁed
in the Union list of novel foods (Commission Implementing Regulation (EU) 2018/1023).
This assessment aims to answer (I) whether the extended uses of chia seeds proposed by the
applicants are safe for human consumption and (II) whether chia seeds can be safely consumed by
the European consumers without speciﬁc precautions and restrictions which would differ from other
foods on the European market.
From an ad hoc literature search regarding chia seeds and process contaminants, EFSA retrieved
one study on wheat-based biscuits (Mesias et al., 2016), which reported that partial replacement of
wheat ﬂour by chia ﬂour as dough ingredient (10%, 15% and 20% chia ﬂour, respectively) and baking
at 190°C resulted in increased formation of the process contaminant acrylamide compared to the
control. None of the applications for the proposed extended uses addressed and considered the
potential formation of processing contaminants in foods with added chia seeds when such foods
undergo thermal processing or cooking procedures.
One of the proposed extended uses of chia seeds concerns their use in bakery wares at a
maximum level of 10% (NF 2018/0519). The Panel considers that baking normally implies heat
treatment above 120°C, temperatures at which acrylamide may be formed. The Panel notes that also
other proposed extended uses may include heat treatment during processing or cooking procedures at
temperatures which may result in the formation of relevant levels of process contaminants such as
acrylamide. In the absence of information that addresses such possible formation of a process
8 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientiﬁc
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
9 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M,
Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance
on the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU)
2015/2283. EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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contaminant in the applications for the proposed extended uses, the safety of the following proposed
uses is not evaluated in this opinion and will be subject of separate assessments:
• Extension of use in bakery wares at a maximum level of 10% (NF 2018/0519);
• Extension of use in cereal and cereal products at a maximum level of 10% (NF 2018/0519);
• Extension of use in herbs, spices, seasonings, soups and broths, sauces, salads and savoury
based sandwich spreads and protein products at a maximum level of 10% (NF 2018/0519);
• Extension of use in total diet replacement foods for weight control as deﬁned by Regulation
(EU) No 609/2013, foods bearing statements on the absence or reduced presence of gluten in
accordance with the requirements of Commission Implementing Regulation (EU) No 828/2014
(NF 2018/0519) at a maximum level of 10% (NF 2018/0519);
• Extension of use in ready-to-eat savouries and snacks at a maximum level of 10% (NF 2018/
0519);
• Extension of use in desserts at a maximum level of 10% (NF 2018/0519).
The present assessment is therefore focused on proposed extended uses that do not raise safety
concerns regarding the formation of acrylamide (because such foods are usually not subject to thermal
processing or cooking procedures and/or are considered not to be among the relevant contributors of
this process contaminant to the overall human exposure (EFSA CONTAM Panel, 2015)). Thus, this
assessment concerns the safety of whole and ground chia seeds including such following proposed
uses in foods:
• Extension of use in chocolate to a maximum of 10% (NF 2018/0183 and NF 2018/0469);
• Increasing the maximum levels in fruit spreads, from the currently authorised level of 1.0% to
a maximum of 10% (NF 2018/0283 and NF 2018/0214);
• Extension of use in fruit desserts at maximum level of 2.5% (NF 2018/0283);
• Extension of use in mixed fruit with coconut milk for a twin pot at maximum level of 6% (NF
2018/0283);
• Extension of use in fruit-preparations to underlay a dairy product at maximum level of 6% (NF
2018/0283);
• Extension of use in fruit-preparations to be mixed with dairy products at maximum level of 6%
(NF 2018/0283);
• Extension of use in confectionary, excluding chewing gums, at a maximum level of 10% (NF
2018/0424 and NF 2018/0519);
• Extension of use in dairy products and analogues at a maximum level of 10% (NF 2018/0519);
• Extension of use in edible ices at a maximum level of 10% (NF 2018/0519);
• Extension of use in fruit and vegetables products at a maximum level of 10% (NF 2018/0519);
• Extension of use in non-alcoholic beverages at a maximum level of 10% (NF 2018/0519);
• Extension of use in compotes from fruit and/or vegetables and/or with cereals at maximum
level of 2% (NF 2018/0542).
3.2. Identity of the NF
The NF is seeds obtained from chia (S. hispanica L.) a summer annual herbaceous plant belonging
to the Labiatae family (EFSA NDA Panel, 2009).
3.3. Production process
The chia seeds are imported from producing countries of South and Central America, Africa and
Australia. The cultivation and the processing of the chia seeds as raw material described in the
submitted applications for the extended uses do not differ from those assessed in the context of the
EFSA NDA Panel Opinion from 2009.
The production processes of the NF as a raw material follow conventional agricultural practices and are
in compliance with Hazard Analysis Critical Control Points (HACCP) principles, when the NF is processed.
3.4. Compositional data
In the EFSA NDA Panel opinion from 2009, compositional data of chia seeds were based on
analytical data from several batches from Bolivia, Peru and Australia. Samples had been analysed
regarding proximate parameters (dry matter, protein, oil, crude ﬁbre and ash) and fatty acids. Further
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analyses had been carried out on the contents of minerals and vitamins, on carbohydrates, the amino
acid proﬁle and the fatty acid proﬁle (EFSA NDA Panel, 2009).
After the EFSA NDA Panel opinion (2009), additional studies have become available which aimed to
further characterise chia seeds. De Falco et al. (2017), among others, gave an overview of
compositional data of chia seeds. They have been reported to contain a broad spectrum of tocopherols,
phytosterols, carotenoids, ﬂavonoids and polyphenolic compounds. Examples of phenolic acids and
ﬂavonoids are shown in Table 1.
Regarding the total phenolic content, the highest amount was found in a study by Martinez-Cruz and
Paredes-Lopez (2014) (1.6  0.2 mg GAE10/g of chia seeds). The authors compared this amount with
the concentrations of total phenolic compounds in other foods of plant origin, such as raspberry (1.1 mg
GAE/g), strawberry (1.6 mg GAE/g), banana (0.9 mg GAE/g), pink guava (1.3 mg GAE/g), mango
(0.6 mg GAE/g), peach (0.8 mg GAE/g), papaya (0.6 mg GAE/g) and pineapple (0.02 mg GAE/g).
According to a study by Da Silva et al. (2017), the amounts of phytic acid in chia seeds range
between 0.96 and 1.16 g/100 g. EFSA (2018) noted the phytic acid content of white and whole wheat
ﬂour (about 0.4 g/100 g and 2.2 g/100 g, respectively), and of rye, rice, barley and oat ﬂours (range:
0.45–0.75 g/ 100 g) as reported by Garcia-Estepa et al. (1999). These authors also indicated that the
Table 1: Phenolic acid derivatives and ﬂavonoids from Salvia hispanica L. seeds
Chemical
constituent
Quantiﬁcation
(lg/g)
Analytical method
(Reference)
Quantiﬁcation in other foods
(Reference)
Caffeic acid 27.4 UHPLC (Martinez-Cruz and
Paredes-Lopez, 2014)
From 50 lg/g in basil to 290 lg/g in
thyme (Kivilompolo and Hyotylainen,
2007)139–149 HPLC (Ayerza, 2013)
30 HPLC (Coelho and de las
Mercedes Salas-Mellado, 2014)
Ferulic acid Traces (LOD:
0.0004)
UHPLC (Martinez-Cruz and
Paredes-Lopez, 2014)
From 1 lg/g in rice, whole grain ﬂour to
722 lg/g in hard wheat, whole grain ﬂour
(Weidner et al., 1999)
Chlorogenic acid 226–218 HPLC (Ayerza, 2013) From 174 lg/g in potatoes tubers to
754 lg/g in potato sprouts (Dao and
Friedman, 1992)
4 UPLC (Coelho and de las
Mercedes Salas-Mellado, 2014)
Rosmarinic acid 927 UHPLC (Martinez-Cruz and
Paredes-Lopez, 2014)
From 910 lg/g in fresh thyme to 829 lg/
g in dried thyme (Zheng and Wang, 2001;
Wang et al., 2004)
Myricetin 115–121 HPLC (Ayerza, 2013) From 14 to 142 lg/g in cranberries
(H€akkinen et al., 1999)
Quercetin 7–6 HPLC (Ayerza, 2013) From 74 to 146 lg/g in lingonberries
(H€akkinen et al., 1999)0.17 UPLC (Coelho and de las,
2014)
Kaempferol 25–24 HPLC (Ayerza, 2013) From 19 lg/g in gooseberries to 5 lg/g in
strawberries (H€akkinen et al., 1999)
Daidzin 6 UHPLC (Martinez-Cruz and
Paredes-Lopez, 2014)
From 16 lg/g in soy sprouts to 339 lg/g
in soy seeds (Morandi et al., 2005)
Glycitein 0.5 UHPLC (Martinez-Cruz and
Paredes-Lopez, 2014)
From 2.8 lg/g in soy raw to 19 lg/g in
soy ﬂour (Wang and Murphy, 1994;
Murphy et al., 1999)
Glycitin 1.4 UHPLC (Martinez-Cruz and
Paredes-Lopez, 2014)
From 6.3 lg/g in soy raw to 114 lg/g in
soy ﬂour (Wang and Murphy, 1994;
Murphy et al., 1999)
Genistein 5.1 UHPLC (Martinez-Cruz and
Paredes-Lopez, 2014)
From 3.5 lg/g in soy sprouts to 20 lg/g
in soy seeds (Morandi et al., 2005)
Genistin 3.4 UHPLC (Martinez-Cruz and
Paredes-Lopez, 2014)
From 13 lg/g in soy sprouts to 423 lg/g
in soy seeds (Morandi et al., 2005)
UHPLC: ultrahigh-performance liquid chromatography; HPLC: high-performance liquid chromatography; LOD: limit of detection
10 Gallic acid equivalents.
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phytic acid content reported in other studies shows a wide variability depending on ﬂour yield, and ﬂour
types (range 0.15–0.32 g/100 g in white ﬂour and 0.96–1.75 g/100 g in whole wheat ﬂour). The
authors reported the phytic acid content of brans (wheat brans: 2.5–5.8 g/100 g; oat brans: 2.0 g/
100 g; rice bran: 5.8 g/100 g). EFSA also notes the phytate content of wheat and whole wheat ﬂour
(0.28 and 0.84 g/100 g, respectively) as reported by OECD in the consensus document on the
composition of Triticum aestivum (OECD, 2003). Thus, the Panel considers that the content of phytates
in chia seeds is comparable to the contents in cereal grains and does not raise a safety concern.
De Souza et al. (2017) investigated the antitryptic activity in chia seeds and reported the
chromatographic isolation of a protein fraction with an estimated molecular mass of approximately 14.4
kDa that exhibited trypsin-inhibitory activity. Crude extract obtained from chia seeds presented 60%
(13 TIU11/mg) of inhibitory activity for trypsin. Guillamon et al. (2008) investigated trypsin inhibitors in
different grain legume seeds from different species and cultivars. Trypsin inhibitor content varied
among species and cultivars, but in general showed the highest values in soybean (43–84 TIU/mg) and
common bean (21–28 TIU/mg).
Another study (Sosa Crespo et al., 2018) retrieved by EFSA, indicated the inhibitory effect of peptide
fractions obtained after hydrolysis of chia seeds and ﬂour against enzymes a-amylase and a-glucosidase,
responsible for the digestion of carbohydrates.
Overall, the Panel notes that, since the last evaluation by EFSA NDA Panel (2009), the knowledge
of the composition of chia seeds has been extended, and no safety concerns were identiﬁed.
3.4.1. Stability of the NF under the intended conditions of use
Among the foods for which the use of chia seeds has been already authorised, there are various
foods that are subject to heat-treatment in the course of their production (e.g. bread, baked products,
breakfast cereals, sterilised ready-to-eat meals based on cereal grains, pseudocereals and/or pulses) or
exhibit a low pH (e.g. fruit juice and fruit/vegetable blend beverages, fruit spreads, yoghurt). The
authorised uses are summarised in Table 3.
The extensions of use of chia seeds which are subject of this assessment (see Section 3.1) could
not only increase levels of some authorised uses, but also represents an extension of the spectrum of
foods to which chia seeds could be added.
Considering the uses subject of this assessment and the composition of chia seeds, the Panel has
no safety concerns regarding the stability of the NF.
3.5. Speciﬁcations
The speciﬁcations of chia seeds are described in the Union list of novel foods (Commission
Implementing Regulation (EU) 2017/2470) and are summarised in Table 2.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the NF
There is a documented history of use of chia seeds in third countries (mainly in Latin America),
dating back hundreds of years. Also, information was provided on the consumption of chia seeds in
countries such as USA, Canada, Australia, New Zealand, Japan and South Korea; in some of them, the
consumption dates to the year 2000 (EFSA NDA Panel, 2009).
Table 2: Speciﬁcations of chia seeds (Salvia hispanica)
Parameter Range
Dry matter 90–97%
Protein 15–26%
Fat 18–39%
Carbohydrate 18–43%
Crude ﬁbre 18–43%
Ash 3–7%
11 Trypsin inhibitor units.
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Since their ﬁrst authorisation in 2009, there has also been a history of use of chia seeds in the EU
(Table 3).
According to the CBI report (2017), the import of chia seeds in Europe reached 16,182 t in 2016,
indicating an average annual increase of 27% (in volume) since 2012. The four top countries
regarding the import of chia seeds are Germany (with a market share of 40%), Netherlands (18%),
Spain (12%) and UK (8%).
3.7. Uses and use levels and anticipated intake
3.7.1. Target population
The target population for the consumption of the NF is the general population.
3.7.2. Uses and use levels
The proposed extensions of use of chia seeds are listed in Section 1.1.
Those proposed extended uses included in this assessment, are indicated in Section 3.1 and
concern the use of chia seeds in chocolate, fruit spreads, fruit desserts, mixed fruit with coconut milk
in twin pot, fruit-preparations to underlay a dairy product, fruit-preparations to be mixed with dairy
products, confectionary (excluding chewing gums), dairy products and analogues, edible ices, fruit and
vegetables products, non-alcoholic beverages, and compotes from fruit and/or vegetables and/or with
cereals. In order to address the terms of reference regarding the overall safety of chia seeds, this
assessment considers the use of chia seeds added to these food groups without the proposed
maximum use levels or other speciﬁc restrictions or precautions.
For the same reason (to assess the overall safety of chia seeds), this assessment also considers the
use of chia seeds without speciﬁc restrictions and precautions regarding their use levels in other foods,
which are usually not subject to thermal processing or cooking procedures.
3.7.3. Anticipated intake of the novel food
The Panel notes that no hazard, which raises safety concerns (except for allergenicity), could be
identiﬁed from the information provided on chia seeds by the applicants (previous and present
applications) or the information retrieved by EFSA through the extensive literature search.
Table 3: Authorised use of chia seeds and products thereof (modiﬁed from the Union list of novel
foods)
Authorised novel
food
Conditions under which the novel food may be used
Speciﬁed food category Maximum levels
Chia seeds (Salvia
hispanica)
Bread products 5% (whole or ground chia seeds)
Baked products 10% whole chia seeds
Breakfast cereals 10% whole chia seeds
Fruit, nut and seed mixes 10% whole chia seeds
Fruit juice and fruit/vegetable blend
beverages
15 g/day for addition of whole, mashed
or ground chia seeds
Pre-packed chia seed as such 15 g/day whole chia seeds
Fruit spreads 1% whole chia seeds
Yoghurt 1.3 g whole chia seeds per 100 g of yoghurt
or 4.3 g whole chia seeds per 330 g of
yoghurt (portion)
Sterilised ready to eat meals based
on cereal grains, pseudocereal grains
and/or pulses
5% whole chia seeds
Chia oil from Salvia
hispanica
Fats and oils 10%
Pure chia oil 2 g/day
Food Supplements as deﬁned in
Directive 2002/46/EC
2 g/day
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In the absence of such hazard and thus, lacking the basis and need to establish safe maximum
intake levels for chia seeds, the Panel considers that exposure assessment for chia seeds does not
provide meaningful information for this assessment.
3.8. Nutritional information
Based on the compositional data, animal studies and the history of use, the Panel considered that
chia seeds are unlikely to be nutritionally disadvantageous to the consumer under the proposed
conditions of use, i.e. 5% of chia seeds in bread (EFSA NDA Panel, 2009).
Since then, the knowledge of the composition of chia seeds has been extended and the Panel has
no concern regarding nutritionally disadvantageous effects resulting from the consumption of chia
seeds.
3.9. Toxicological information
The applicants referred to a publication, which summarises the results of four toxicological studies
with chia seeds (Shu-Qin et al., 2013). These studies were conducted according to the National
Standards of the People’s Republic of China for the toxicological assessment of food (GB15193.3-
2003). It is not indicated whether the studies were conducted in compliance with Good Laboratory
Practice (GLP) and, based on the short description and limited data presented, the Panel cannot assess
whether the protocols applied were in line with the respective OECD test guidelines.
An acetone extract of chia seeds was tested for induction of gene mutations using the plate
incorporation method and only four Salmonella Typhimurium tester strains (TA97, TA98, TA100 and
TA102). No increase in the number of revertant colonies was observed at dose levels up to 5 mg/plate
in the absence and presence of a metabolic activation system when compared with the solvent control.
In an in vivo micronucleus test using bone marrow, chia seeds ground into a powder, which was
passed through a sieve and suspended in maize oil, was used as test material. After oral
administration twice within 24 h at dose levels up to 7.5 g/kg body weight (bw) to Kunming mice
(n = 5/sex per group), no increase in the frequency of micronucleated polychromatic erythrocytes
(PCE) compared with the control group (which received maize oil) and no cytotoxicity of the test
material was observed.
No statistically signiﬁcant increase in the rate of abnormal sperms was observed after
administration of the same test material to male Kunming mice (n = 5/group) at dose levels up to
7.5 g/kg bw.
In an acute oral toxicity study with Kunming mice (n = 10/sex), no adverse effects were identiﬁed
after administration of chia seed powder (mixed with maize oil) at a dose of 22.5 g/kg bw.
The Panel considers that the available toxicological studies do not indicate a safety concern.
3.9.1. Human data
After the EFSA NDA Panel opinion in 2009, a number of human studies have been conducted on
chia seeds, primarily investigating putative beneﬁcial effects resulting from their consumption.
The applicants provided eight articles on human studies (Nieman et al., 2009, 2012; Vuksan et al.,
2010, 2017a; Illian et al., 2011; Guevara-Cruz et al., 2012; Jin et al., 2012; Ho et al., 2013) and three
reviews (Ulbricht et al., 2009; Ali et al., 2012; Teoh et al., 2018). EFSA retrieved six additional human
studies in literature search (Brissette et al., 2013; Toscano et al., 2014, 2015; Nieman et al., 2015;
Ayaz et al., 2017; Vuksan et al., 2017b) and three review articles (De Souza Ferreira et al., 2015;
Parker et al., 2018; Grancieri et al., 2019).
The highest amounts of chia seeds were used in a single-blinded, placebo-controlled study by
Nieman et al. (2009), in amounts of 50 g/day for 12 weeks with 76 adults. This study included
endpoints such as serum lipoproteins, serum glucose, blood pressure, plasma cytokines and serum
CRP (C-reactive protein). In addition, symptom logs consisted of measures of digestive health
(constipation, heartburn, bloating, diarrhoea and nausea), sickness (fever, cough, sore throat, stuffy
nose, runny nose and headache) and overall well-being. The same endpoints were also studied by
Nieman et al. (2012) among 56 postmenopausal women consuming 25 g chia seeds or control (poppy)
seeds in their randomised controlled trial for 10 weeks.
Other studies had a duration of up to half a year (Brissette et al., 2013; Vuksan et al., 2017a) with
the number of participants ranging from 10 (Jin et al., 2012) to 77 (Vuksan et al., 2017a) and average
dose levels of 30 g/day. Some of these studies, although not primarily designed to assess the safety of
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chia seeds, reported safety-related parameters such as anthropometrics (body mass and composition),
blood pressure, clinical chemistry (urea, creatinine, alanine transaminase (ALT), serum lipid proﬁle,
serum glucose and lactate, serum cortisol, inﬂammation markers) and haematology parameters
(complete blood counts, prothrombin time). Also, adverse events that were reported by symptom logs
consisting of measures of digestive health (constipation, heartburn, bloating, diarrhoea and nausea),
hunger levels and energy levels (morning, afternoon and evening), sickness (fever, cough, sore throat,
stuffy nose, runny nose and headache), pain (joint, muscle and back), allergies, dry eyes, ﬁngernail
growth, stress level, focus/concentration and overall well-being (Nieman et al., 2009, 2012, 2015; Jin
et al., 2012; Brissette et al., 2013; Toscano et al., 2014, 2015; Vuksan et al., 2017a).
The Panel notes that the human studies provided by the applicants and those found by an
extensive literature search were primarily designed to investigate putative beneﬁcial effects at intakes
up to 50 g per day and addressed only a limited number of safety-relevant endpoints such as blood
pressure, standard clinical chemistry and some haematology parameters. The Panel notes that no
changes were found in the studied safety-related parameters and no adverse events related to the
consumption of chia seeds were reported. The Panel notes, however, the inherent limitations of such
human studies for their use in this safety assessment.
3.10. Allergenicity
In 2009, the Panel noted the cross-reactivity of sera from subjects allergic to peanuts and sesame
and reiterated its earlier opinion from 2005 that it was not possible to predict the potential allergenicity
of chia seeds.
Since then, two case reports were identiﬁed in the available literature, both cases within the EU
(Spain).
Garcıa Jimenez et al. (2015) described the ﬁrst case of an immunoglobulin E (IgE)-mediated
anaphylactic reaction induced by chia seeds. A few days after starting to consume chia seeds, a 54-
year-old male patient experienced the following symptoms: pruritus in his mouth, followed by
generalised urticaria, facial angioedema, shortness of breath, and dizziness. The authors identiﬁed
known water-soluble and liposoluble allergens which include lectin, an elongation factor, and an 11S
globulin as well as three additional undescribed allergens.
Tomas-Perez et al. (2018) reported another case of IgE-mediated reaction with an atypical clinical
manifestation (i.e. eczema and dermatitis) induced by chia seeds. A 46-year-old male patient
complained of eczematous and itchy lesions on his hands after the introduction of chia seeds in his
diet. A skin prick testing with chia seed extract was found positive. The authors identiﬁed allergens of
molecular weights of around 60, 30, 15 and 10 kDa as responsible for sensitisation, and argued that
allergens with 10 kDa could be lipid transfer proteins (LTPs) because they were proven to be resistant
both to heat and pepsin digestion.
There is no information available on the prevalence of chia seeds allergy. The information available
indicates that allergic reactions upon consumption of chia seeds may occur.
4. Discussion
This assessment concerns the safety of chia seeds for the general population under extended uses.
These include the use of chia seeds without speciﬁc restriction or precaution in chocolate, fruit
spreads, fruit desserts, mixed fruit with coconut milk in twin pot, fruit-preparations to underlay a dairy
product, fruit-preparations to be mixed with dairy products, confectionary (excluding chewing gums),
dairy products and analogues, edible ices, fruit and vegetables products, non-alcoholic beverages, and
compotes from fruit and/or vegetables and/or with cereals. The assessment also takes into account
the use of chia seeds without speciﬁc restrictions or precautions regarding their use for other foods
which are usually not subject to thermal processing or cooking procedures.
This assessment does not address the safety of chia seeds when added to foods other than those
covered by the preceding paragraph which may undergo heat treatment during processing and/or
cooking procedures at temperatures which may result to the formation of relevant levels of the
process contaminants, such as acrylamide. In the absence of sufﬁcient information regarding the
formation of this process contaminant in heated foods with added chia seeds, the safety of those
proposed extended uses is subject of separate assessments.
The composition of chia seeds on proximate parameters (dry matter, protein, oil, crude ﬁbre and
ash) and fatty acids was assessed by the Panel in the EFSA opinion in 2009. Data on the contents of
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minerals and vitamins, carbohydrates, amino- and fatty acid proﬁles, total polyphenols, tannins and
rosmarinic acid and contaminants, such as heavy metals and mycotoxins were also assessed. Since
2009, several new studies have become available which provide further information on the presence of
tocopherols, phytosterols, carotenoids, ﬂavonoids and polyphenolic compounds but also antinutrients,
such as phytates and some enzyme inhibitors in chia seeds. The Panel considers that their occurrence
in chia seeds does not raise any safety concern.
Since the ﬁrst authorisation for placing of chia seeds on the Union market as a NF in 2010, the
safety of chia seeds for extensions of use was assessed several times by the Member States which did
not identify any hazard which may pose a risk for the consumers.
For the present assessment, the Panel took into account previous safety assessments (EFSA NDA
Panel, 2005, 2009), the information presented in seven applications, the history of consumption since
2010, and the information gathered from an extensive literature search designed to identify hazards
related to chia seeds, toxicological and human studies.
Chia seeds have been consumed in North and South America, Australia, New Zealand and Asian
countries as Japan, South Korea and other countries. The history of use in countries as USA, Canada
and Australia extends nowadays to up to approximately 20 years, while its consumption in Europe
reaches over a decade now. The Panel considers that the history of use of chia seeds supports the
safety assessment of the NF.
The Panel considers that the limited available toxicological studies do not indicate safety concerns.
Available human trials with intake levels of up to 50 g of chia seeds per day were primarily designed
to investigate putative beneﬁcial effects and addressed only a limited number of safety-relevant
endpoints such as blood-pressure, standard clinical chemistry and some haematology parameters. The
Panel notes that no adverse events related to the consumption of chia seeds were reported, noting
however the inherent limitations of such human studies for their use in this safety assessment.
In 2009, the Panel expressed the uncertainty related to the potential allergenicity of chia and noted
the cross-reactivity of sera from patients known to be allergic to peanuts and sesame. Since then, the
available information from two case reports (Garcıa Jimenez et al., 2015; Tomas-Perez et al., 2018)
indicates that allergic reactions upon consumption of chia seeds may occur.
The Panel notes that no other hazard causing safety concerns has been identiﬁed on the basis of
the available information on composition, stability, history of consumption, toxicological and human
data regarding whole and ground chia seeds.
The Panel considers that an exposure estimate for chia seeds does not provide meaningful
information for safety assessment.
5. Conclusions
The Panel concludes that chia seeds are safe under the assessed conditions of use.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request to carry out an overall dietary exposure and safety assessment for chia seeds
(Salvia hispanica L.) as a novel food. Ref. Ares(2018)3762383, dated 16 July 2018 and
subsequent amendments Ref. Ares(2018)4459892, dated 30 August 2018 and Ref. Ares
(2018)5097094, dated 04 October 2018.
2) On 16 July 2018, EFSA received a valid application from the European Commission on
extension of use of chia seeds as NF, which was submitted by SANCHIS MIRA S.A. and the
scientiﬁc evaluation procedure started.
3) On 09 October 2018, EFSA received four valid applications from the European Commission
on extension of use of chia seeds as NF, which were submitted by Zentis GmbH & Co. KG, by
Majami Sp. z o.o. Sp. k., by Naturkost €Ubelh€or GmbH & Co. KG and by The Chia Co and the
scientiﬁc evaluation procedures started.
4) On 16 November 2018, EFSA received two valid applications from the European Commission
on extension of use of chia seeds as NF, which were submitted by Parry’s Pots Limited (PPL),
and by Materne SAS and the scientiﬁc evaluation procedures started.
5) During its meeting on 14 March 2019, the NDA Panel, having evaluated the data, adopted a
scientiﬁc opinion on the safety of chia seeds (Salvia hispanica L.) as a NF for extended uses
pursuant to Regulation (EU) 2015/2283.
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